Works by Eldor, Roy

Results: 51
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1111, doi. 10.1111/dom.13194
    By:
    • Pratley, Richard E.;
    • Eldor, Roy;
    • Raji, Annaswamy;
    • Golm, Gregory;
    • Huyck, Susan B.;
    • Sunga, Sheila;
    • Johnson, Jeremy;
    • Engel, Samuel S.;
    • Lauring, Brett;
    • Qiu, Yanping;
    • Terra, Steven G.;
    • Mancuso, James P.
    Publication type:
    Article
    10

    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 530, doi. 10.1111/dom.13116
    By:
    • Dagogo‐jack, Samuel;
    • Liu, Jie;
    • Eldor, Roy;
    • Amorin, Guillermo;
    • Johnson, Jeremy;
    • Hille, Darcy;
    • Liao, Yuqin;
    • Huyck, Susan;
    • Golm, Gregory;
    • Terra, Steven G.;
    • Mancuso, James P.;
    • Engel, Samuel S.;
    • Lauring, Brett
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Exenatide modulates visual cortex responses.

    Published in:
    2019
    By:
    • Binda, Paola;
    • Eldor, Roy;
    • Huerta, Claudia;
    • Adams, John;
    • Lancaster, John;
    • Fox, Peter;
    • Del Prato, Stefano;
    • DeFronzo, Ralph;
    • Abdul‐Ghani, Muhammad;
    • Daniele, Giuseppe;
    • Abdul-Ghani, Muhammad
    Publication type:
    journal article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50